(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 March 2020 (19.03.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/055756 A1

(51) International Patent Classification:
A61K 31/18 (2006.01) *A61K 31/4523* (2006.01)
A61K 31/44 (2006.01)

(21) International Application Number:
PCT/US2019/050227

(22) International Filing Date:
09 September 2019 (09.09.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/729,189 10 September 2018 (10.09.2018) US

(71) Applicant: **MIRATI THERAPEUTICS, INC.** [US/US]; 9393 Towne Center Dr., Suite 200, San Diego, CA 92121 (US).

(72) Inventors: **ENGSTROM, Lars, Daniel**; 7974 Amargosa Dr., Carlsbad, CA 92009 (US). **ARANDA, Ruth, Wei**; 10797 San Diego Mission Rd., Unit 311, San Diego, CA 92108 (US). **OLSON, Peter**; 4763 Robbins St., San Diego, CA 92122 (US). **CHRISTENSEN, James, Gail**; 4276 Kerwood Ct., San Diego, CA 92130 (US). **HALLIN, Jill**; 1326 Felton St, San Diego, CA 92102 (US).

(74) Agent: **POLYAKOV, Mark V.** et al.; Wood, Phillips, Katz, Clark & Mortimer, 500 West Madison Street, Suite 1130, Chicago, IL 60661 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: COMBINATION THERAPIES

(57) Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a pan ErbB family inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

WO 2020/055756 A1